Elicio Therapeutics Inc.

Elicio Therapeutics Inc. a clinical-stage biotechnology company engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002 an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004 an AMP-modified CpG adjuvant a component of ELI-002 to treat or prevent a range of diseases; ELI-003 for cancers involving an ALK mutation; ELI-011 for hematological cancers; ELI-005 a product for the prevention of COVID-19; and ELI-002 7P (AMPLIFY-7P) a vaccine for mutated solid tumors. The company's AMP platform enables to develop differentiated treatment modalities including therapeutic vaccines adjuvants and cell therapy AMPlifiers. The company was formerly known as VEDANTRA PHARMACEUTICALS INC. and changed its name to Elicio Therapeutics Inc. on September 18 2019. The company was incorporated in 2011 and is headquartered in Boston Massachusetts.